Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) Director Jon P. Stonehouse bought 10,000 shares of Bellicum Pharmaceuticals stock in a transaction on Friday, November 9th. The stock was acquired at an average price of $4.56 per share, for a total transaction of $45,600.00. Following the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at $45,600. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
NASDAQ:BLCM opened at $4.21 on Wednesday. Bellicum Pharmaceuticals Inc has a 52 week low of $3.92 and a 52 week high of $10.40. The company has a current ratio of 8.01, a quick ratio of 8.01 and a debt-to-equity ratio of 0.39. The firm has a market capitalization of $180.82 million, a price-to-earnings ratio of -1.48 and a beta of 1.06.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last issued its quarterly earnings data on Tuesday, November 6th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.58) by $0.03. The firm had revenue of $0.29 million during the quarter, compared to analyst estimates of $0.07 million. On average, research analysts predict that Bellicum Pharmaceuticals Inc will post -2.39 EPS for the current fiscal year.
A number of research firms have commented on BLCM. BidaskClub upgraded Bellicum Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 14th. ValuEngine upgraded Bellicum Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, October 22nd. Zacks Investment Research upgraded Bellicum Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.25 target price on the stock in a research report on Friday, November 9th. Cantor Fitzgerald set a $18.00 target price on Bellicum Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, August 7th. Finally, Citigroup reduced their target price on Bellicum Pharmaceuticals from $22.00 to $19.00 and set a “buy” rating on the stock in a research report on Thursday, August 9th. One analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $13.42.
WARNING: This piece was originally posted by WKRB News and is owned by of WKRB News. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://www.wkrb13.com/2018/11/14/bellicum-pharmaceuticals-inc-blcm-director-jon-p-stonehouse-buys-10000-shares-of-stock.html.
About Bellicum Pharmaceuticals
Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include BPX-501, an adjunct T cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation; and BPX-601, a GoCAR-T product candidate in Phase I clinical trial for treating solid tumors expressing the prostate stem cell antigen.
Featured Story: Closed-End Mutual Funds (CEFs)
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.